LSTA
LISATA THERAPEUTICS, INC.
$3.56
+2.30%
$32.4M
No data for this timeframe.
Vol
Market Cap$32.4M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (78%)
Inst. Holders15 funds
Inst. Value$3.0M
Inst. Activity1 buys / 0 sells
SEC Reports4
Press Releases2
Recent Activity
Jun 9, 2026
SEC
Lisata Therapeutics entered into an amendment and waiver to its existing merger agreement with Kuva Labs, extending the
8-K — Impact 6/10
Jun 5, 2026
SEC
Kuva Labs informed Lisata Therapeutics it will not commence the previously-agreed tender offer on June 1, 2026, citing o
8-K — Impact 7/10
May 29, 2026
SEC
Lisata Therapeutics amended its merger agreement with Kuva Labs, reducing the upfront cash consideration from $5.00 to $
8-K — Impact 6/10
Inst.
STATE STREET CORP — ADD
25,348 shares ($127.0K)
Inst.
DIMENSIONAL FUND ADVISORS LP — TRIM
14,253 shares ($26.5K)
Jun 10, 2026
Press
Lisata Therapeutics announced that Kuva Acquisition Corp. has commenced a tender offer to acquire all outstanding shares
Impact 7/10
Jun 10, 2026
m_and_a
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
<p align="center"><em>Lisata stockholders to receive $4.00 per share in cash at closing, plus one no
Mar 6, 2026
Press
Lisata Therapeutics (LSTA) has agreed to be acquired by private company Kuva Labs in a deal valuing each share at $5.00
Impact 8/10
Price Targets
$4.00
+12.4% upside
Buy
Current $3.56
Low $4.00
Median $4.00
High $4.00
1 analysts
$4.00
$4.00
Analyst Ratings
2Strong Buy
5Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 15, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy → Neutral |
| Jan 21, 2026 | Brookline Capital | DOWNGRADE | Buy → Hold |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $-1.09 ▼ -13.5% | $-1.09 — $-1.09 | 43% YoY | 1 |
| Next FY | $-1.16 ▼ -75.8% | $-1.16 — $-1.16 | -6% YoY | 1 |
Latest Reports
BULLISH
Press
7/10
Lisata Therapeutics announced that Kuva Acquisition Corp. has commenced a tender offer to acquire all outstanding shares
Jun 10, 2026
BEARISH
8-K
6/10
Lisata Therapeutics entered into an amendment and waiver to its existing merger agreement with Kuva Labs, extending the
Jun 9, 2026
BEARISH
8-K
7/10
Kuva Labs informed Lisata Therapeutics it will not commence the previously-agreed tender offer on June 1, 2026, citing o
Jun 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | — | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.4M | — |
| RENAISSANCE TECHNOLOGIES LLC | $659.9K | — |
| BlackRock, Inc. | $274.8K | — |
| VANGUARD FIDUCIARY TRUST CO | $174.9K | — |
15 institutional holders with $3.0M total value (592,521 shares) as of 2026-Q1. Top holders: FMR, VANGUARD, RENAISSANCE. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | — | $0.00 | 0.0% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 271,815 | $1.4M | 45.9% | — |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 131,715 | $659.9K | 22.2% | — |
| 4 | BlackRock, Inc. | 54,857 | $274.8K | 9.3% | — |
| 5 | VANGUARD FIDUCIARY TRUST CO | 34,917 | $174.9K | 5.9% | — |
| 6 | STATE STREET CORP | 25,348 | $127.0K | 4.3% | ADD +76.7% |
| 7 | CITADEL ADVISORS LLC | 22,666 | $113.6K | 3.8% | — |
| 8 | Cerity Partners LLC | 12,183 | $61.0K | 2.1% | — |
| 9 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 11,604 | $58.1K | 2.0% | — |
| 10 | BANK OF AMERICA CORP /DE/ | 10,353 | $51.9K | 1.7% | — |
| 11 | HighTower Advisors, LLC | 10,042 | $50.3K | 1.7% | — |
| 12 | ROYAL BANK OF CANADA | 5,912 | $29.0K | 1.0% | DOUBLED +11269.2% |
| 13 | Vanguard Global Advisers, LLC | 1,033 | $5.2K | 0.2% | — |
| 14 | MORGAN STANLEY | 75 | $376.00 | 0.0% | TRIM -63.9% |
| 15 | CITIGROUP INC | 1 | $5.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| STATE STREET CORP | ADD | 14,348 | 25,348 | +76.7% | $127.0K | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 20,947 | 14,253 | -32.0% | $26.5K | 2025-Q4 |
| MORGAN STANLEY | TRIM | 208 | 75 | -63.9% | $140.00 | 2025-Q4 |
| UBS Group AG | DOUBLED | 1 | 7,069 | +706800.0% | $20.5K | 2025-Q2 |
| ROYAL BANK OF CANADA | DOUBLED | 52 | 5,912 | +11269.2% | $14.0K | 2025-Q1 |
| BARCLAYS PLC | TRIM | 7 | 4 | -42.9% | — | 2024-Q4 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 17,340 | 25,226 | +45.5% | $75.2K | 2024-Q4 |
| UBS Group AG | NEAR_EXIT | 125 | 1 | -99.2% | $3.00 | 2024-Q4 |
| MORGAN STANLEY | TRIM | 2,550 | 1,466 | -42.5% | $4.4K | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
4 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 1 mixed, 0 neutral. Avg impact: 6.5/10.
BEARISH
8-K
6/10
Lisata Therapeutics entered into an amendment and waiver to its existing merger agreement with Kuva
Jun 9, 2026
BEARISH
8-K
7/10
Kuva Labs informed Lisata Therapeutics it will not commence the previously-agreed tender offer on Ju
Jun 5, 2026
MIXED
8-K
6/10
Lisata Therapeutics amended its merger agreement with Kuva Labs, reducing the upfront cash considera
May 29, 2026
BEARISH
8-K
7/10
Lisata Therapeutics has announced that Kuva Labs, the acquiring company, has delayed the commencemen
Apr 15, 2026
Current analyst consensus: Buy (78% buy). Based on 9 analysts: 2 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$4.00 mean target
+12.4% upside
Buy (3.00)
$4.00 Low
$4.00 High
| Metric | Value |
|---|---|
| Current Price | $3.56 |
| Target Low | $4.00 |
| Target Mean | $4.00 |
| Target Median | $4.00 |
| Target High | $4.00 |
| # Analysts | 1 |
| Recommendation | Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$-1.09 | $-1.09 | $-1.09 | 42.9% | -13.5% | — | $0.0B | -100.0% | 1 |
| Next FY 2027-12-31 |
$-1.16 | $-1.16 | $-1.16 | -6.4% | -75.8% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
2 analyst firms have rated this stock: 0 upgrades, 2 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 15, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Jan 21, 2026 | Brookline Capital | DOWNGRADE | Buy | Hold |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| May 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 10, 2026
m_and_a
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
<p align="center"><em>Lisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent value right, which represen
May 26, 2026
Clinical Trial
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
Phase Phase 2 — TERMINATED
May 6, 2026
earnings_calendar
LSTA Q1 2026 Earnings Scheduled — 2026-05-06
May 4, 2026
Clinical Trial
A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction
Phase Phase 2 — TERMINATED
Mar 6, 2026
m_and_a
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
<p align="center"><em>Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential ad
Feb 26, 2026
earnings_calendar
LSTA Q4 2025 Earnings After Market Close — 2026-02-26